【英文タイトル】Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026



1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026

4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026

5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2015-2026
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Data Expected in July 2016
6.3.2 Other Visual Cycle Modulators
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine’s Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2015-2026
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Cortiject (Santen): Prodrug Candidate
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

8. Regional Market Breakdown, 2015-2026
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2016-2026
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and R&D Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges

10. Research Interviews
10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
10.1.1 Major Changes in AMD and Other Retinal Diseases Market
10.1.2 The Landscape of Emerging Markets
10.1.3 Opportunities and Plans of Marken’s Network
10.1.4 DR Market Opportunities
10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
10.2.1 MC-1101: Progress in Clinical Trials
10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
10.2.3 Partnerships and Expected Launch of MC-1101

11. Report Conclusions
11.1 The Age of Lucentis: Nearing Its Conclusion?
11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
11.3 Indications Outside Wet AMD to Gain in Importance
11.4 Dry AMD Market Has Huge Potential
11.5 Fovista Most Prominent Among the Pipeline Candidates
11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form


■ タイトル:黄斑変性症(AMD)及びその他の網膜疾患治療薬の世界市場
■ 英文:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
■ 発行日:2016年2月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041528
■ 調査対象地域:グローバル